PET projects

Biogen and AC Immune collaborate to develop PET reagents for PD and ALS

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc. (NASDAQ:BIIB) are taking the learnings into other neurodegenerative diseases with a collaboration to develop PET imaging agents for Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS),

Read the full 619 word article

How to gain access

Continue reading with a
two-week free trial.